Los Angeles Capital Management’s Beam Therapeutics BEAM Stock Holding History

Los Angeles Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$538K	Buy	15,687 +15,238	+3,394%	+$460K	﹤0.01%	895
2026 Q1	$10.7K	Hold	449	–	–	﹤0.01%	1938
2025 Q4	$10.7K	Buy	+449	New	+$11.5K	﹤0.01%	2055
2024 Q3	–	Sell	-16,787	Closed	-$393K	–	1176
2024 Q2	$393K	Sell	16,787 -1,105	-6%	-$27.1K	﹤0.01%	928
2024 Q1	$591K	Hold	17,892	–	–	﹤0.01%	824
2023 Q4	$487K	Sell	17,892 -6,873	-28%	-$171K	﹤0.01%	876
2023 Q3	$596K	Sell	24,765 -2,084	-8%	-$55.9K	﹤0.01%	779
2023 Q2	$857K	Buy	26,849 +4,301	+19%	+$140K	﹤0.01%	685
2023 Q1	$690K	Sell	22,548 -2,410	-10%	-$95.1K	﹤0.01%	765
2022 Q4	$976K	Buy	24,958 +7,601	+44%	+$340K	﹤0.01%	717
2022 Q3	$827K	Buy	17,357 +861	+5%	+$49.1K	﹤0.01%	765
2022 Q2	$639K	Buy	16,496 +4,199	+34%	+$167K	﹤0.01%	873
2022 Q1	$705K	Buy	12,297 +4,200	+52%	+$275K	﹤0.01%	900
2021 Q4	$645K	Sell	8,097 -106	-1%	-$9.08K	﹤0.01%	891
2021 Q3	$714K	Hold	8,203	–	–	﹤0.01%	894
2021 Q2	$1.06M	Sell	8,203 -220	-3%	-$17.5K	﹤0.01%	829
2021 Q1	$674K	Buy	+8,423	New	+$801K	﹤0.01%	1084

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Los Angeles Capital Management's BEAM Position: Q2 2026 in Review

Los Angeles Capital Management increased its Beam Therapeutics (BEAM) stake by 3,394% in Q2 2026, buying an estimated $460K and bringing the position to 15,687 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #895.

Los Angeles Capital Management first reported a position in BEAM in Q1 2021 and has held it in 17 quarters since. The position peaked at $1.06M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Los Angeles Capital Management held 15,687 shares of Beam Therapeutics worth $538K as of Q2 2026.
Los Angeles Capital Management bought 15,238 Beam Therapeutics shares in Q2 2026, an estimated $460K.
Beam Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #895 holding.
Los Angeles Capital Management first reported a position in Beam Therapeutics in Q1 2021 and has held it in 17 quarters since.
Los Angeles Capital Management's Beam Therapeutics position peaked at $1.06M in Q2 2021.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.